Aptamer technology: a new approach to treat lymphoma?

Youli Zu

doi:10.1097/BS9.0000000000000033

Aptamer technology: a new approach to treat lymphoma?

Youli Zu

Research output: Contribution to journal › Review article › peer-review

4 Scopus citations

Abstract

Oligonucleotide aptamers are a class of small-molecule ligands. Functionally similar to protein antibodies, aptamers can specifically bind to their targets with high affinity. Biomedical studies have revealed the potential clinical value of aptamer technology for disease diagnosis and targeted therapy. Lymphoma is a group of cancers originating from the lymphatic system. Currently, chemotherapy is the primary treatment for lymphoma, although it may cause serious side effects in patients due to lack of target specificity. Here, we selectively discuss the recent development of potential applications of aptamer technology for precision lymphoma therapy, which are able to not only achieve high therapeutic efficacy but also do not cause off-target side effects.

Original language	English (US)
Pages (from-to)	11-15
Number of pages	5
Journal	Blood Science
Volume	2
Issue number	1
DOIs	https://doi.org/10.1097/BS9.0000000000000033
State	Published - Jan 1 2020

Keywords

Immunotherapy
Lymphoma
Oligonucleotide aptamer
Precision therapy
Target therapy

ASJC Scopus subject areas

Hematology

Access to Document

10.1097/BS9.0000000000000033

Cite this

@article{a855d545396c4111ac9a65ee1554e255,

title = "Aptamer technology: a new approach to treat lymphoma?",

abstract = "Oligonucleotide aptamers are a class of small-molecule ligands. Functionally similar to protein antibodies, aptamers can specifically bind to their targets with high affinity. Biomedical studies have revealed the potential clinical value of aptamer technology for disease diagnosis and targeted therapy. Lymphoma is a group of cancers originating from the lymphatic system. Currently, chemotherapy is the primary treatment for lymphoma, although it may cause serious side effects in patients due to lack of target specificity. Here, we selectively discuss the recent development of potential applications of aptamer technology for precision lymphoma therapy, which are able to not only achieve high therapeutic efficacy but also do not cause off-target side effects.",

keywords = "Immunotherapy, Lymphoma, Oligonucleotide aptamer, Precision therapy, Target therapy",

author = "Youli Zu",

note = "Funding Information: The author would like to thank Dr. Adrienne Winston for her scientific editing of this paper. This study was partially supported by NIH grant R01 CA224304. Publisher Copyright: {\textcopyright} 2020 De Gruyter Open Ltd. All rights reserved.",

year = "2020",

month = jan,

day = "1",

doi = "10.1097/BS9.0000000000000033",

language = "English (US)",

volume = "2",

pages = "11--15",

journal = "Blood Science",

issn = "2543-6368",

publisher = "Lippincott Williams and Wilkins",

number = "1",

}

TY - JOUR

T1 - Aptamer technology

T2 - a new approach to treat lymphoma?

AU - Zu, Youli

N1 - Funding Information: The author would like to thank Dr. Adrienne Winston for her scientific editing of this paper. This study was partially supported by NIH grant R01 CA224304. Publisher Copyright: © 2020 De Gruyter Open Ltd. All rights reserved.

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Oligonucleotide aptamers are a class of small-molecule ligands. Functionally similar to protein antibodies, aptamers can specifically bind to their targets with high affinity. Biomedical studies have revealed the potential clinical value of aptamer technology for disease diagnosis and targeted therapy. Lymphoma is a group of cancers originating from the lymphatic system. Currently, chemotherapy is the primary treatment for lymphoma, although it may cause serious side effects in patients due to lack of target specificity. Here, we selectively discuss the recent development of potential applications of aptamer technology for precision lymphoma therapy, which are able to not only achieve high therapeutic efficacy but also do not cause off-target side effects.

AB - Oligonucleotide aptamers are a class of small-molecule ligands. Functionally similar to protein antibodies, aptamers can specifically bind to their targets with high affinity. Biomedical studies have revealed the potential clinical value of aptamer technology for disease diagnosis and targeted therapy. Lymphoma is a group of cancers originating from the lymphatic system. Currently, chemotherapy is the primary treatment for lymphoma, although it may cause serious side effects in patients due to lack of target specificity. Here, we selectively discuss the recent development of potential applications of aptamer technology for precision lymphoma therapy, which are able to not only achieve high therapeutic efficacy but also do not cause off-target side effects.

KW - Immunotherapy

KW - Lymphoma

KW - Oligonucleotide aptamer

KW - Precision therapy

KW - Target therapy

UR - http://www.scopus.com/inward/record.url?scp=85105193997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85105193997&partnerID=8YFLogxK

U2 - 10.1097/BS9.0000000000000033

DO - 10.1097/BS9.0000000000000033

M3 - Review article

AN - SCOPUS:85105193997

SN - 2543-6368

VL - 2

SP - 11

EP - 15

JO - Blood Science

JF - Blood Science

IS - 1

ER -

Aptamer technology: a new approach to treat lymphoma?

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this